Your browser is no longer supported. Please, upgrade your browser.
KALA [NASD]
Kala Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.09 Insider Own2.20% Shs Outstand56.96M Perf Week-18.31%
Market Cap430.78M Forward P/E- EPS next Y-0.71 Insider Trans0.00% Shs Float55.43M Perf Month-0.94%
Income-95.20M PEG- EPS next Q-0.69 Inst Own77.70% Short Float16.84% Perf Quarter0.82%
Sales5.30M P/S81.28 EPS this Y27.80% Inst Trans-3.87% Short Ratio4.18 Perf Half Y-14.62%
Book/sh1.76 P/B4.18 EPS next Y60.30% ROA-43.90% Target Price- Perf Year23.08%
Cash/sh2.62 P/C2.80 EPS next 5Y- ROE-87.60% 52W Range5.04 - 14.68 Perf YTD8.55%
Dividend- P/FCF- EPS past 5Y-22.70% ROI-55.90% 52W High-49.86% Beta0.40
Dividend %- Quick Ratio7.50 Sales past 5Y169.20% Gross Margin51.70% 52W Low46.03% ATR0.66
Employees136 Current Ratio7.70 Sales Q/Q83.30% Oper. Margin- RSI (14)38.11 Volatility8.31% 8.02%
OptionableYes Debt/Eq0.72 EPS Q/Q13.20% Profit Margin- Rel Volume0.76 Prev Close7.36
ShortableYes LT Debt/Eq0.72 EarningsFeb 25 BMO Payout- Avg Volume2.23M Price7.36
Recom1.70 SMA20-15.82% SMA50-7.06% SMA200-18.21% Volume1,688,795 Change0.00%
Sep-14-20Downgrade Jefferies Buy → Hold $10
Jul-23-20Initiated Northland Capital Outperform
Jun-01-20Resumed Oppenheimer Outperform $21
May-27-20Reiterated H.C. Wainwright Buy $14 → $17
Mar-09-20Upgrade BofA/Merrill Neutral → Buy
Dec-17-19Downgrade BofA/Merrill Buy → Neutral $9 → $6
Mar-14-19Initiated Jefferies Buy $15
Mar-02-21 08:00AM  
Feb-25-21 07:00AM  
06:15AM  
Feb-18-21 08:00AM  
Feb-17-21 04:01PM  
Feb-16-21 07:00AM  
Feb-03-21 12:31PM  
Feb-01-21 01:31AM  
Jan-20-21 04:01PM  
Jan-07-21 07:00AM  
Jan-04-21 08:00AM  
Dec-27-20 02:39AM  
Dec-18-20 04:01PM  
Dec-16-20 03:51PM  
Nov-27-20 01:39AM  
Nov-18-20 04:05PM  
Nov-16-20 07:00AM  
Nov-11-20 08:00AM  
Nov-05-20 08:45AM  
07:00AM  
06:15AM  
Oct-29-20 08:17PM  
12:34PM  
08:00AM  
Oct-28-20 10:24AM  
06:21AM  
Oct-27-20 03:38PM  
11:22AM  
07:00AM  
Oct-19-20 04:05PM  
Oct-15-20 11:06AM  
Oct-08-20 08:50AM  
Oct-06-20 08:48AM  
Oct-05-20 10:15AM  
Sep-30-20 10:01AM  
Sep-18-20 04:05PM  
Sep-10-20 08:00AM  
Sep-08-20 08:00AM  
Aug-27-20 11:00AM  
Aug-07-20 09:26AM  
Aug-06-20 09:15AM  
07:00AM  
Aug-04-20 08:00AM  
Jul-30-20 04:01PM  
Jul-28-20 01:01PM  
12:33PM  
Jul-17-20 04:01PM  
Jun-23-20 11:01AM  
Jun-10-20 08:00AM  
Jun-05-20 11:30AM  
Jun-02-20 08:41AM  
May-28-20 08:16AM  
May-27-20 08:00AM  
May-26-20 11:41AM  
08:00AM  
May-19-20 11:30AM  
May-09-20 10:01PM  
May-07-20 10:05AM  
08:23AM  
07:00AM  
May-06-20 08:00AM  
May-05-20 12:00PM  
09:03AM  
May-04-20 08:00AM  
May-01-20 11:30AM  
Apr-30-20 08:00AM  
Apr-17-20 04:01PM  
Apr-16-20 12:00PM  
Apr-08-20 11:01AM  
10:42AM  
Apr-07-20 11:30AM  
Apr-03-20 04:01PM  
Mar-20-20 08:30PM  
Mar-15-20 04:24PM  
Mar-11-20 11:06AM  
10:50AM  
Mar-10-20 11:02PM  
04:44PM  
11:30AM  
09:31AM  
09:24AM  
Mar-09-20 06:00AM  
Mar-06-20 10:11AM  
Feb-20-20 04:01PM  
Feb-12-20 11:30AM  
08:35AM  
07:00AM  
Feb-09-20 03:22PM  
Feb-06-20 11:53AM  
08:00AM  
Feb-03-20 11:11AM  
Jan-30-20 11:10AM  
Jan-22-20 09:45AM  
09:33AM  
Jan-15-20 08:00AM  
Jan-14-20 09:21AM  
Jan-08-20 08:00AM  
Dec-19-19 09:53PM  
04:05PM  
Dec-12-19 04:11PM  
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Watertown, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chen HongmingChief Scientific OfficerFeb 25Option Exercise2.3047,000108,100233,515Feb 26 05:35 PM
Bazemore ToddChief Operating OfficerOct 22Buy7.604030442Oct 28 08:36 PM
Trachtenberg EricSee RemarksJun 19Option Exercise5.1928,901149,99628,901Jun 22 04:06 PM
Reumuth MaryChief Financial OfficerJun 09Option Exercise2.6443,477114,77148,293Jun 11 04:58 PM
Bazemore ToddChief Operating OfficerJun 05Buy13.392272Oct 28 08:36 PM
Brazzell Romulus KChief Medical OfficerApr 09Option Exercise2.9967,771202,377176,496Apr 13 08:38 AM
Chen HongmingChief Scientific OfficerMar 30Option Exercise2.3031,00071,30086,849Apr 01 04:43 PM
Bazemore ToddChief Operating OfficerMar 16Buy5.7510,00057,50010,000Mar 17 05:46 PM
Grunberg GregoryDirectorMar 13Buy7.892,534,85419,999,9982,534,854Mar 16 07:59 AM
Shah Rajeev M.DirectorMar 13Buy7.896,337,13549,999,99510,874,613Mar 13 06:47 PM
RA CAPITAL MANAGEMENT, L.P.DirectorMar 13Buy7.896,337,13549,999,99510,874,613Mar 13 06:45 PM